ストックスクリーナーアプリを入手
1.22
7.96%
0.09
前日終値:
$1.13
開ける：
$1.15
24時間の取引高:
2.04M
Relative Volume:
1.21
時価総額：
$141.84M
収益：
$6.65M
当期純損益:
$-136.32M
株価収益率:
-1.063
EPS:
-1.1477
ネットキャッシュフロー:
$-112.04M
1週間 パフォーマンス:
+15.09%
1か月 パフォーマンス:
-17.57%
6か月 パフォーマンス:
+25.67%
1年 パフォーマンス:
+35.15%
1日の値動き範囲:
$1.15
$1.285
1週間の範囲:
$1.04
$1.285
52週間の値動き範囲:
$0.6611
$1.9399
Fate Therapeutics Inc Stock (FATE) Company Profile
名前
Fate Therapeutics Inc
セクター
電話
858.875.1803
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.22 | 131.38M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-11-18 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-06-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-01-06 | ダウングレード | Cowen | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | ダウングレード | Stifel | Buy → Hold |
| 2023-01-06 | ダウングレード | Truist | Buy → Hold |
| 2023-01-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 開始されました | Goldman | Sell |
| 2022-11-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-08-18 | 再開されました | Wells Fargo | Overweight |
| 2022-07-28 | 開始されました | Needham | Hold |
| 2022-07-11 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 開始されました | Robert W. Baird | Neutral |
| 2022-02-11 | 再開されました | BMO Capital Markets | Market Perform |
| 2021-12-15 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-11-09 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-07 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Jefferies | Buy |
| 2021-02-26 | 開始されました | BofA Securities | Buy |
| 2021-02-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-02-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-27 | 再開されました | H.C. Wainwright | Neutral |
| 2020-05-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-09 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 繰り返されました | Mizuho | Buy |
| 2019-12-09 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-06 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-06-07 | 開始されました | ROTH Capital | Neutral |
| 2019-05-31 | 開始されました | Guggenheim | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2019-03-28 | 開始されました | SVB Leerink | Outperform |
| 2019-01-03 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 開始されました | Jefferies | Buy |
| 2018-08-01 | 開始されました | Citigroup | Buy |
| 2018-03-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
すべてを表示
Fate Therapeutics Inc (FATE) 最新ニュース
Mizuho reiterates Fate Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Take Profit: Will Fate Therapeutics Inc outperform small cap indexes2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Fate Therapeutics Inc stock faces analyst caution amid biotech pipeline scrutiny - AD HOC NEWS
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed - marketscreener.com
FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 14.1% in February - MarketBeat
Big Picture: Can Fate Therapeutics Inc beat the S P 5002026 Intraday Action & Trade Opportunity Analysis Reports - baoquankhu1.vn
FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference - MarketBeat
Performance Recap: Can Fate Therapeutics Inc ride the EV waveProduct Launch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Valuation Update: Can Fate Therapeutics Inc lead its sector in growthWeekly Trading Summary & AI Powered Market Entry Strategies - baoquankhu1.vn
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates - MSN
Fate Therapeutics at Leerink Global Healthcare Conference: Strategic Shift in Focus - Investing.com Canada
FATE: FT819 shows promising efficacy and safety in lupus nephritis, with pivotal trials set for later this year - TradingView
Dividend Watch: Can Fate Therapeutics Inc. ride the EV waveCEO Change & Risk Controlled Daily Trade Plans - baoquankhu1.vn
CEO Change: Can Fate Therapeutics Inc keep up with sector leaders2026 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn
Fate Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Risk Analysis: Can Fate Therapeutics Inc lead its sector in growthJuly 2025 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Fed Meeting: Can Fate Therapeutics Inc beat the S P 5002025 Technical Patterns & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Bull Bear: Can Fate Therapeutics Inc lead its sector in growthFed Meeting & Fast Entry and Exit Trade Plans - baoquankhu1.vn
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewswire
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Sahm
FATE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Growth Value: Is Fate Therapeutics Inc subject to activist investor interestQuarterly Market Summary & High Return Trade Opportunity Guides - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail
Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations - MarketBeat
Fate Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Baird reiterates Fate Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Fate Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Fate Therapeutics: Fourth Quarter Earnings Overview - Bitget
Biotechnology company Fate Therapeutics Inc announced that its current cash reserves are sufficient to sustain company operations until the end of 2027. - Bitget
FATE THERAPEUTICS INC SEC 10-K Report - TradingView
Fate Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - The Manila Times
Fate Therapeutics reports lower Q4 collaboration revenue - TradingView
Form 10-K FATE THERAPEUTICS INC For: Dec 31 - StreetInsider
Earnings Summary: Fate Therapeutics Q4 - Benzinga
Fate Therapeutics (NASDAQ: FATE) cuts 2025 expenses, extends cash runway - Stock Titan
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World
Bond Watch: What are AFBIs technical support levels2025 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn
Aug Patterns: Will Fate Therapeutics Inc outperform small cap indexes2025 Price Action Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
Fate Therapeutics (FATE) to Release Earnings on Wednesday - MarketBeat
Critical Review: Fate Therapeutics (NASDAQ:FATE) vs. TuHURA Biosciences (NASDAQ:HURA) - Defense World
Will Fate Therapeutics Inc. outperform the market in YEARTrade Entry Report & Expert-Curated Trade Recommendations - mfd.ru
Is Fate Therapeutics Inc. stock risky to hold now2025 Geopolitical Influence & Advanced Technical Signal Analysis - mfd.ru
Fate Therapeutics Inc (FATE) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):